Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-27T15:52:00.086Z Has data issue: false hasContentIssue false
  • English
  • Français

Non-Stimulant Trials of Adult ADHD

Published online by Cambridge University Press:  07 November 2014

Lenard A. Adler
Lenard A. Adler*
Affiliation:
Dr. Adler is director of the Adult ADHD Program at the, New York University School of Medicine in New York City
Get access Rights & Permissions [Opens in a new window]

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a lifelong condition that begins in childhood and continues with adult manifestations related to the core symptoms. Approximately 50% to 75% of children with ADHD continue to meet criteria for the disorder as adolescents and adults. Adults with the disorder increasingly present to primary care physicians, psychiatrists, and other practitioners for diagnosis and treatment. Understanding the diagnosis of ADHD in adults requires knowledge of age-dependent decline of symptoms over time. Retrospective recall of symptoms and impairment are valid methods of diagnosing the disorder. ADHD is also a brain disorder with a strong neurobiologic basis, complex etiology, and genetic component. Genetic and environmental vulnerabilities give rise to abnormalities in the brain and subsequent behavioral and cognitive deficits, which may produce the symptoms associated with ADHD. Magnetic resonance imaging studies of ADHD have provided evidence that abnormalities in the brain are caused by the disorder itself rather than treatment of the disorder. Psychiatric comorbidity is common among patients with ADHD and tends to complicate treatment. Acute and long-term use of long-acting stimulant formulations (methylphenidate and amphetamine compounds) have shown robust efficacy and tolerability consistent with the treatment response established in children with ADHD. Non-stimulant medications have demonstrated efficacy as well, and may be preferred in patients with tic and substance use disorders.

In this expert roundtable supplement, Timothy E. Wilens, MD, reviews the epidemiology and clinical presentation of adult ADHD. Next, Joseph Biederman, MD, provides an overview of recent advances in the neurobiology of ADHD. Thomas J. Spencer, MD, reviews stimulant treatment of adult ADHD, and Lenard A. Adler concludes with a discussion of non-stimulant trials in adult ADHD.

Type
Research Article
Information
CNS Spectrums , Volume 12 , Issue S6 , 2007 , pp. 11 - 13
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Spencer, T, Biederman, J, Wilens, T. Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin N Am. 2004;27:373–383.CrossRefGoogle ScholarPubMed
2.Michelson, D, Adler, L, Spencer, T, et al.Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112–120.CrossRefGoogle ScholarPubMed
3.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC; American Psychiatric Association; 1994.Google Scholar
4.Adler, L, Dietrich, A, Reimherr, F, et al.Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry. 2006;18:107–113.CrossRefGoogle ScholarPubMed
5.Biederman, J, Baldessarini, RJ, Wright, V, Knee, D, Harmatz, J. A double-blind placebo-controlled study of desipramine in the treatment of attention deficit disorder: I. Efficacy. J Am Acad Child Adolesc Psychiatry. 1989;28:777–784.CrossRefGoogle ScholarPubMed
6.Wilens, TE, Biederman, J, Prince, J, et al.Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153:1147–1153.Google ScholarPubMed
7.Wilens, TE, Biederman, JB, Mick, E, Spencer, T. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit/hyperactivity disorder. J Nerv Ment Dis. 1995;183:48–50.CrossRefGoogle ScholarPubMed
8.Adler, LA, Resnick, S, Kunz, M. Devinsky, O. Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol Bull. 1995;31(4):785–788.Google ScholarPubMed
9.Hornig-Rohan, M, Amsterdam, J. Venlafaxine versus stimulant therapy in patients with dual diagnoses of ADHD and depression. Presented at: Annual Meeting of the New Clinical Drug Evaluation Unit; June 10-14, 1995; Orlando, Florida. Poster #92.Google Scholar
10.Findling, R, Schwartz, M, Flannery, D, Manos, M. Venlafaxine in adults with ADHD: an open trial. J Clin Psychiatry. 1996;57:184–189.Google Scholar
11.Wilens, TE. Biederman, J. Spencer, TJ. Venlafaxine for adult ADHD. [Case Reports. Letter] Am J Psychiatry. 1995;152(7):1099–1100.Google ScholarPubMed
12.Hedges, D, Reimherr, FW, Rogers, A, et al.An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull. 1995;31(4):779–783.Google ScholarPubMed
13.Barrickman, L, Perry, P, Allen, A, et al.Bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:649–657.CrossRefGoogle ScholarPubMed
14.Wilens, TE, Spencer, TJ, Biederman, J, et al.A controlled clinical trial of bupropion for attention-deficit/hyperactivity disorder in adults. Am J Psychiatry. 2001;158:282–288.CrossRefGoogle ScholarPubMed
15.Wilens, TE, Haight, BR, Horrigan, JP, et al.Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005;57(7):793–801.CrossRefGoogle ScholarPubMed
16.Zametkin, A, Rapoport, JL, Murphy, DL, et al.Treatment of hyperactive children with monoamine oxidase inhibitors: I. Clinical efficacy. Arch Gen Psychiatry. 1985;42:962–966.CrossRefGoogle ScholarPubMed
17.Ernst, M, Liebenauer, LL, Jons, PH, et al.Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety. Psychopharmacol Bull. 1996;32:327–334.Google ScholarPubMed
18.Trott, GE, Friese, HJ, Menzel, M, Nissen, G. [Use of moclobemide in children with attention-deficit/hyperactivity disorder] Jugendpsychiat. 1991;19:248–353.Google Scholar
19.Biederman, J, Swanson, JM, Wigal, SB, et al.A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry. 2006;67(5):727–735.CrossRefGoogle ScholarPubMed
20.Greenhill, LL, Biederman, J, Boellner, SW, et al.A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(5):503–511.CrossRefGoogle ScholarPubMed
21.Swanson, JM, Greenhill, LL, Lopez, FA, et al.Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry. 2006;67(1):137–147.CrossRefGoogle ScholarPubMed
22.Biederman, J, Swanson, JM, Wigal, SB, et al.Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics. 2005;116(6):777–784.CrossRefGoogle ScholarPubMed
23.Wigal, SB, Biederman, J, Swanson, JM, Yang, R, Greenhill, LL. Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: pooled analysis of 3 randomized, double-blind, placebo-controlled studies. Prim Care Companion J Clin Psychiatry. 2006;8(6):352–360.Google ScholarPubMed
24.Taylor, FB, Russo, J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol. 2000;10(4):311–320.CrossRefGoogle ScholarPubMed
25.Turner, DC, Clark, L, Dowson, J, et al.Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004;55(10):1031–1040.CrossRefGoogle ScholarPubMed
26.Conners, CK, Levin, ED, Sparrow, E, et al.Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull. 1996;32(1):67–73.Google ScholarPubMed
27.Wilens, TE, Verlinden, MH, Adler, LA, Wozniak, PJ, West, SA. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry. 2006;59(11):1065–1070.CrossRefGoogle ScholarPubMed
28.Wilens, TE, Biederman, J, Spencer, TJ, et al.A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1999;156(12):1931–1937.CrossRefGoogle ScholarPubMed
29.Connor, DF, Fletcher, KE, Swanson, JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999;38:1551–1559.CrossRefGoogle ScholarPubMed
30.Scahill, L, Chappell, PB, Kim, YS, et al.A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067–1074.CrossRefGoogle ScholarPubMed
31.Taylor, FB, Russo, J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001;21(2):223–228CrossRefGoogle ScholarPubMed
32.Wilens, TE. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry. 2004;65(Suppl 3):38–45.Google ScholarPubMed
33.Allen, AJ, Kurlan, RM, Gilbert, DL, et al.Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65(12):1941–1949.CrossRefGoogle ScholarPubMed